{"schema_version":"secwatch.filing_event.v1","accession":"0001665988-26-000041","form_type":"8-K","ticker":"BVS","cik":"0001665988","company_name":"Bioventus Inc.","filed_at":"2026-08-05T11:40:11+00:00","discovered_at":"2026-08-05T11:45:03.277603+00:00","generated_at":"2026-08-05T11:45:24.853371+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Bioventus Q2 revenue $153.2M (+4%), GAAP EPS $0.47; initiates strategic alternatives review","bullets":["Q2 revenue $153.2M (+4% YoY); GAAP EPS $0.47 vs $0.11; non-GAAP EPS $0.22 vs $0.21.","Pain Treatments revenue $81.7M (+11.5%); Surgical Solutions $50.4M (-4.5%); Restorative Therapies $21.1M (-2.4%).","Reaffirmed FY2026 guidance: net sales $600-610M, adjusted EPS $0.75-0.79, cash from ops $84-89M.","Board formed independent committee to evaluate strategic alternatives including sale, after unsolicited proposal.","Made $20M discretionary principal prepayment on term loan during Q2."],"urls":{"canonical":"https://secwatch.observer/filing/0001665988-26-000041","json":"https://secwatch.observer/filing/0001665988-26-000041.json","markdown":"https://secwatch.observer/filing/0001665988-26-000041.md","text":"https://secwatch.observer/filing/0001665988-26-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000166598826000041/0001665988-26-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000166598826000041/bvs-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T11:45:24.853371+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}